These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 8692472)

  • 1. Alpha- and beta-emitting radiolanthanides in targeted cancer therapy: the potential role of terbium-149.
    Allen BJ; Blagojevic N
    Nucl Med Commun; 1996 Jan; 17(1):40-7. PubMed ID: 8692472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted alpha therapy: evidence for potential efficacy of alpha-immunoconjugates in the management of micrometastatic cancer.
    Allen BJ
    Australas Radiol; 1999 Nov; 43(4):480-6. PubMed ID: 10901964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modeling Cell and Tumor-Metastasis Dosimetry with the Particle and Heavy Ion Transport Code System (PHITS) Software for Targeted Alpha-Particle Radionuclide Therapy.
    Lee D; Li M; Bednarz B; Schultz MK
    Radiat Res; 2018 Sep; 190(3):236-247. PubMed ID: 29944461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current and potential therapeutic uses of lanthanide radioisotopes.
    Cutler CS; Smith CJ; Ehrhardt GJ; Tyler TT; Jurisson SS; Deutsch E
    Cancer Biother Radiopharm; 2000 Dec; 15(6):531-45. PubMed ID: 11190486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A unique matched quadruplet of terbium radioisotopes for PET and SPECT and for α- and β- radionuclide therapy: an in vivo proof-of-concept study with a new receptor-targeted folate derivative.
    Müller C; Zhernosekov K; Köster U; Johnston K; Dorrer H; Hohn A; van der Walt NT; Türler A; Schibli R
    J Nucl Med; 2012 Dec; 53(12):1951-9. PubMed ID: 23139086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Electron- and positron-emitting radiolanthanides for therapy: aspects of dosimetry and production.
    Uusijärvi H; Bernhardt P; Rösch F; Maecke HR; Forssell-Aronsson E
    J Nucl Med; 2006 May; 47(5):807-14. PubMed ID: 16644751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advancements in cancer therapy with alpha-emitters: a review.
    Imam SK
    Int J Radiat Oncol Biol Phys; 2001 Sep; 51(1):271-8. PubMed ID: 11516878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Which radionuclide, carrier molecule and clinical indication for alpha-immunotherapy?
    Guerard F; Barbet J; Chatal JF; Kraeber-Bodere F; Cherel M; Haddad F
    Q J Nucl Med Mol Imaging; 2015 Jun; 59(2):161-7. PubMed ID: 25752501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radioimmunotherapy with alpha-emitting nuclides.
    McDevitt MR; Sgouros G; Finn RD; Humm JL; Jurcic JG; Larson SM; Scheinberg DA
    Eur J Nucl Med; 1998 Sep; 25(9):1341-51. PubMed ID: 9724387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radioimmunoconjugates for targeted alpha therapy of malignant melanoma.
    Abbas Rizvi SM; Sarkar S; Goozee G; Allen BJ
    Melanoma Res; 2000 Jun; 10(3):281-9. PubMed ID: 10890383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiobiologic implications of the microscopic distribution of energy from radionuclides.
    Adelstein SJ; Kassis AI
    Int J Rad Appl Instrum B; 1987; 14(3):165-9. PubMed ID: 3312115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dosimetric aspects of radiolabeled antibodies for tumor therapy.
    Humm JL
    J Nucl Med; 1986 Sep; 27(9):1490-7. PubMed ID: 3528417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radioimmunotherapy of cancer with high linear energy transfer (LET) radiation delivered by radionuclides emitting α-particles or Auger electrons.
    Aghevlian S; Boyle AJ; Reilly RM
    Adv Drug Deliv Rev; 2017 Jan; 109():102-118. PubMed ID: 26705852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radioimmunotherapy with alpha-particle emitting radioimmunoconjugates.
    Zalutsky MR; Bigner DD
    Acta Oncol; 1996; 35(3):373-9. PubMed ID: 8679269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radioimmunotherapy with α-particle-emitting radionuclides.
    Seidl C
    Immunotherapy; 2014; 6(4):431-58. PubMed ID: 24815783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dosimetric characterization of radionuclides for systemic tumor therapy: influence of particle range, photon emission, and subcellular distribution.
    Uusijärvi H; Bernhardt P; Ericsson T; Forssell-Aronsson E
    Med Phys; 2006 Sep; 33(9):3260-9. PubMed ID: 17022220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Innovation, Impact, and Strategic Importance of Alpha-Emitting Radionuclides.
    Mirzadeh S
    J Med Imaging Radiat Sci; 2019 Dec; 50(4 Suppl 1):S21-S25. PubMed ID: 31420270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Global comparison of targeted alpha vs targeted beta therapy for cancer: In vitro, in vivo and clinical trials.
    Marcu L; Bezak E; Allen BJ
    Crit Rev Oncol Hematol; 2018 Mar; 123():7-20. PubMed ID: 29482781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted Radiotherapy with Alpha-Particle Emitting Radionuclides Seminar, November 18, 2004, Cracow, Poland.
    Zalutsky MR; Petelenz B
    Nucl Med Rev Cent East Eur; 2004; 7(2):195. PubMed ID: 15968616
    [No Abstract]   [Full Text] [Related]  

  • 20. Radioimmunotherapy with alpha-particle emitting radionuclides.
    Zalutsky MR; Pozzi OR
    Q J Nucl Med Mol Imaging; 2004 Dec; 48(4):289-96. PubMed ID: 15640792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.